- Price
- $10.09
- Day
- -1.75%
- Mkt Cap
- $3.83B
- 52W Range
- $5.10 – $13.08
- Volume
- 10.78M
- Beta
- 0.63
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
First FDA-approved IHC assay identifies patients who may be eligible for combination treatment with TRUQAP® (capivasertib) BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma.
Read full article
Patterson-UTI's longer contracts, higher dayrates and packed frac calendar point to better cash flow, but losses and commodity exposure remain.
Read full article
PTEN expects about 100 average U.S. rigs in Drilling Services during the third quarter, with adjusted gross profit projected at around $145 million.
Read full article
After a week of wild swings that rattled portfolios and left investors guessing, Wall Street analysts are already reshuffling their ratings on Friday morning, with some surprising cuts and upgrades across sectors from utilities to gaming that could reshape how you think about your positions.
Read full article
Patterson-UTI Energy, Inc. (PTEN) Q2 2026 Earnings Call Transcript
Read full article
Patterson-UTI Energy NASDAQ: PTEN reported second-quarter revenue of $1.228 billion, up 10% from the first quarter, as stronger drilling activity, higher pricing and near-full utilization of completion equipment lifted results across its operating segments.
Read full article
HOUSTON, TX / ACCESS Newswire / July 29, 2026 / PATTERSON-UTI ENERGY, INC. (NASDAQ:PTEN) today reported financial results for the quarter ended June 30, 2026.
Read full article
While the top- and bottom-line numbers for Patterson-UTI (PTEN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read full article
Patterson-UTI (PTEN) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.06 per share a year ago.
Read full article
PTEN to report Q2 results on July 29, with estimates pointing to a narrower loss as lower operating costs offset pressure from weaker revenues.
Read full article
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read full article
The mean of analysts' price targets for Patterson-UTI (PTEN) points to a 25.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read full article